Dual-regulated myoD- and msx1-based interventions in C2C12-derived cells enable precise myogenic/osteogenic/adipogenic lineage control

The Journal of Gene Medicine
C FuxMartin Fussenegger

Abstract

Advanced gene therapy, tissue engineering and biopharmaceutical manufacturing require sophisticated and well-balanced multiregulated multigene interventions to reprogram desired mammalian cell phenotypes. We have combined the streptogramin (PIP)- and tetracycline (TET)-responsive gene regulation systems for independent expression control of the differentiation determinants myoD and msx1 in C2C12-derived cells. Different dual-regulated expression scenarios which induce either both, only one or none of the lineage control genes triggered differential differentiation and precise control of myogenic, osteogenic or adipogenic cell phenotypes. Our findings substantiate the use of multiregulated multigene interventions in reprogramming cellular differentiation pathways in a desired manner.

References

Jun 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·M Gossen, H Bujard
Nov 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M CrescenziS A Aaronson
Jan 1, 1995·Developmental Dynamics : an Official Publication of the American Association of Anatomists·H G SimonC Tabin
Mar 1, 1995·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·M A Rudnicki, R Jaenisch
Oct 1, 1994·Current Opinion in Genetics & Development·M E Buckingham
Dec 1, 1994·Current Opinion in Cell Biology·A B LassarB Novitch
Dec 6, 1997·Current Opinion in Genetics & Development·K Walsh, H Perlman
Sep 4, 1999·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·S Huang
Mar 25, 2000·Clinical Genetics·L A Sabourin, M A Rudnicki
Oct 12, 2000·Proceedings of the National Academy of Sciences of the United States of America·M SchuldinerN Benvenisty
Oct 26, 2000·The Journal of Biological Chemistry·M FolcherC J Thompson
Nov 4, 2000·Nature Biotechnology·M FusseneggerJ E Bailey
Feb 13, 2001·Cell·S J OdelbergM T Keating
Apr 13, 2001·Current Biology : CB·S M Hughes
May 22, 2001·Cellular and Molecular Life Sciences : CMLS·M Kitzmann, A Fernandez
Jul 27, 2001·Molecular Aspects of Medicine·G M Rubanyi
Sep 3, 2002·Nature Biotechnology·Wilfried WeberMartin Fussenegger

❮ Previous
Next ❯

Citations

Aug 5, 2008·Tissue Engineering. Part a·Carlota Diaz Sanchez-BustamanteMartin Fussenegger
Mar 30, 2006·The Journal of Gene Medicine·Wilfried Weber, Martin Fussenegger
Oct 15, 2013·Cell Biochemistry and Function·Hailong MuJinlian Hua
Oct 7, 2004·Current Opinion in Biotechnology·Wilfried Weber, Martin Fussenegger
Sep 12, 2006·Metabolic Engineering·Laetitia MalphettesMartin Fussenegger
Jan 30, 2014·BMC Developmental Biology·Philippos Mourikis, Shahragim Tajbakhsh

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.